Board of directors

Thomas Pollare
Thomas Pollare
Chairman and member of the board since 2017.

Born: 1953

Education/experience: Thomas Pollare holds an M.D. from Karolinska Institutet and a Ph.D. from Uppsala University. He was previously a partner in the Venture Capital company 3i. He has held VP positions at both Pharmacia Corp and Schering-Plough Inc. He has been responsible for the market approval of several pharmaceutical products in various therapeutic areas and which generated billions in annual sales. He has previous experience of board work in both start-up companies and private equity investments.

Current assignments: Chairman of the Board and CEO of Oncolution AB. Chairman of the Boards of AC Intressenter AB, Sinfonia Biotherapeutics AB, AlzeCure Discovery AB, Stiftelsen AlzeCure and A3P Biomedical AB. Member of the boards of SSI Diagnostics Holding A/S och Psilox AB. Alternate member of the board of BioWorks Technologies AB.

Completed assignments (past five years): Chairman of the boards of BioWorks Technologies AB, QuiaPEG Pharmaceuticals AB and QuiaPEG Pharmaceuticals Holding AB. Member of the boards of Pharmaceuticals Sales & Development Sweden AB, Cereno Scientific AB, Premacure Holding AB, Premacure AB, Xellia Pharmaceuticals ApS, Centro Gamma Knife Santiago S.a.P Chile, Gamma Knife Center Ecuador S.APT and GammaKnife Center Indonesia.

Holding: 881,887 shares and 35,000 share options.

Dependent in relation to the company and company management, but independent in relation to the company’s largest shareholders.

Ellen Donnelly
Ellen Donnelly
Board member since 2018.

Born: 1974

Education/experience: Ellen Donnelly has a Ph.D. from Yale University Medical School (USA). Ellen has previously held various executive positions in clinical development, project management, research and strategy at Pfzer. Prior to joining Pfzer, Ellen held various positions in American biotechnology and management consultancy companies. Ellen was recently CEO of Modus Therapeutics, a Swedish biotech company that focuses on sickle cell diseases.

Current assignment: CEO, Abliva AB.

Completed assignments (past five years): CEO of Modus Therapeutics Holding AB (publ) and Modus Therapeutics AB. CEO, Epigenetics Division of Juvenescence; CEO, Souvien Therapeutics.

Holding: No shareholding.

Independent in relation to the company, company management and the company’s major shareholders

Eva Lilienberg
Eva Lilienberg
Board member since 2021.

Born: 1956

Education/experience:  Eva Lilienberg holds an MSc in Pharmaceutical sciences. Eva has a broad regulatory and commercial international experience. She has also a solid experience of drug development from various senior management positions within New Products/Regulatory Affairs area at Merck, Sharp & Dohme (MSD).and have led international teams in purpose to optimize development programs to get pharmaceutical products approved, reimbursed and commercially viable. Eva has worked actively with inter alia FDA and EMA. Eva has also held various positions in Astra, Draco (now AstraZeneca) and HMR (now Sanofi). She has acted as Regulatory Affairs consultant in small and mid size companies. Certified Director by the Swedish Academy of Board of Directors.

Current assignments: Consultant and CEO of Kapitel Tre AB. Board member of the Regulatory Affairs section of the Swedish Society of Pharmaceutical Sciences.

Completed assignments (past five years): Service Area lead/Principal Consultant for drug development project at NDA Regulatory Services AB.

Holding: No shareholding

Independent in relation to the company, company management and the company’s major shareholders.

Ragnar Linder
Ragnar Linder
Board member since 2017.

Born: 1953

Education/experience: Ragnar Linder has a Master of Science degree in Chemical Engineering from KTH Royal Institute of Technology. Ragnar is a co-founder of Pygargus, a research company in the field of realworld evidence, which was bought by IMS Health (currently IQVIA) in 2013 and in which Ragnar has held senior positions ever since. He has also held several senior positions in Amgen Nordic (CEO), Aventis, HMR and Hoechst. Ragnar has also been a member of the boards of several biotech, pharmaceutical and CRO companies. Today, Ragnar is an independent consultant.

Current assignments: Member of the board of Pharmacolog i Uppsala AB and 3D Trace AB.

Completed assignments (last five years): Senior Principle, Iqvia Inc. and member of the board of R. Linder Holding AB.

Holding: 30, 429 shares and 25,000 share options.

Independent in relation to the company, company management and the company’s major shareholders.

Holdings in AlzeCure Pharma AB as of May 17, 2020.